Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/16/2025

Reversal Agents for Rivaroxaban-Associated Bleeding

Introduction to Reversal Agents

  • The American College of Cardiology recommends andexanet alfa as the specific reversal agent for rivaroxaban in patients with life-threatening or uncontrolled bleeding 1, 2

Primary Reversal Agent: Andexanet Alfa

  • Andexanet alfa is FDA-approved for reversing rivaroxaban-associated major bleeding and is the preferred agent over prothrombin complex concentrates, according to the American College of Cardiology 2
  • Andexanet alfa reduces anti-factor Xa activity by 92-93% within 2-5 minutes of administration in rivaroxaban-treated patients 1
  • In the ANNEXA-4 study, 80% of patients achieved excellent or good hemostatic efficacy at 12 hours after andexanet administration 1, 4

Mechanism and Efficacy

  • Andexanet alfa acts as a decoy protein, binding rivaroxaban with high affinity and preventing it from inhibiting endogenous factor Xa 1, 4

Clinical Indications for Andexanet

  • The American College of Cardiology recommends administering andexanet alfa for life-threatening bleeding, bleeding in closed spaces or critical organs, persistent major bleeding despite local hemostatic measures, and emergency surgery with high bleeding risk when rivaroxaban cannot be cleared 2

Alternative Reversal Strategies

  • If andexanet alfa is unavailable, 4F-PCC can be considered as a second-line option, though evidence is limited and it lacks FDA approval for this indication, according to the American College of Cardiology 2
  • Suggested dosing for 4F-PCC is 25-50 units/kg IV, with 25 units/kg preferred initially as it provides effective hemostasis without increased thromboembolic events 2, 6

Important Caveats

  • The reversal effect of andexanet alfa is transient, with anti-factor Xa activity returning toward baseline approximately 2 hours after infusion completion 3
  • Thrombotic events occur in approximately 10% of patients within 30 days, emphasizing the need for careful consideration of when to resume anticoagulation 1

Resuming Anticoagulation

  • Prompt resumption of anticoagulation after bleeding control significantly reduces thrombotic risk, according to the American College of Cardiology 2, 3
  • Timing should be individualized based on bleeding severity, thrombotic risk, and bleeding control 2